Renal cell carcinoma, VHL-associated
Jump to navigation Jump to search
|Page editor||Section editor|
|Teja Ganta, MD
Icahn School of Medicine at Mount Sinai
New York, NY, USA
|Ali Raza Khaki, MD|
Palo Alto, CA, USA
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
All lines of therapy
|Study||Dates of enrollment||Evidence|
|Jonasch et al. 2021 (MK-6482-004)
|2018-05-31 to 2019-03-29||Phase 2 (RT)|
- Belzutifan (Welireg) 120 mg PO once per day
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed NCT03401788